Business Wire

Joe Tucci Joins 83North As Special Advisor

Jaa

83North, the international venture capital firm with operations in Europe and Israel, today announced the appointment of Joe Tucci as a Special Advisor.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170619005026/en/

Joe Tucci (Photo: Business Wire)

Joe Tucci (Photo: Business Wire)

Until September 2016, Tucci was the CEO and Chairman of EMC. He joined EMC in 2000 and led it to become one of the world’s leading and most respected technology companies. In 2016, EMC merged with Dell, a global IT company. The deal was one of the biggest technology mergers in recent history and valued EMC at $67 billion. Tucci stepped down from the organisation following the closure of the deal. Today, he is the Co-CEO and Co-Chairman of GTY Technology Holdings and the Chairman of Bridge Growth Partners.

"I have previously worked with the partners at 83North and I believe in their approach to venture investing,” said Tucci. “I am keeping a close eye on the areas they invest in globally, many of which are going through massive inflection points of innovation. I am looking forward to sharing my experience and advising their portfolio companies.”

“We are thrilled to have Joe join us as an advisor,” said Gil Goren, General Partner at 83North. “I worked under Joe’s leadership for many years at EMC and I am certain he will make a significant contribution to our firm and portfolio. Scaling companies is a tough task, and very few leaders have done it to the extent Joe has achieved at EMC. His experience and network will add significant value to 83North and we look forward to working together.”

83North is a global venture capital firm with a simple focus – backing exceptional entrepreneurs that create category-leading global companies. Notable past and present investments include market leaders such as Just Eat, Hybris (acquired by SAP), ScaleIO (acquired by EMC), Social Point (acquired by Take2), Celonis, Guardicore, iZettle, Payoneer, Via, Actifio and Zerto.

83North recently closed its fourth venture fund at $250 million. With offices in Tel Aviv and London, the fund is operating globally, managing over $800 million, and investing in companies created by European and Israeli entrepreneurs.

About 83North

83North started life as Greylock IL, an affiliate fund of Greylock Partners. Today, 83North is an independent firm investing in European and Israeli entrepreneurs. 83North is committed to help build global leading companies, with more than half of its portfolio companies having operations in the US.

Visit www.83north.com and follow @83NorthVC on Twitter.

Contact information

Touchdown PR for 83North
Hannah Finch
+44(0) 1252 717040
hfinch@touchdownpr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity18.6.2018 15:25Tiedote

The Procter & Gamble Company (NYSE: PG) today advanced its commitment to gender equality through a series of new actions, commitments and partnerships to increase diversity throughout the creative supply chain, leading to more accurate and positive portrayals of women in advertising and media, and driving growth and social good. Women and girls are inaccurately or negatively portrayed in 29 percent of ads and media programs*, and women continue to be underrepresented behind the camera: only 32 percent of Chief Marketing Officers, 33 percent of Chief Creative Officers and a mere 10 percent of Commercial Directors are women. These issues persist despite evidence that gender-equal ads perform 10 percent higher in trust and 26 percent higher in sales growth*. To address these issues, P&G has called for an aspiration to achieve 100% accurate and positive portrayals of women in advertising and media, supported by equal representation of women and men in the creative supply chain. P&G is lead

Norsk Titanium Marks Milestone in U.S. Production18.6.2018 15:00Tiedote

Norsk Titanium (NTi), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, announced today a major milestone in qualified production. NTi’s Plattsburgh, New York Development and Qualification Center (PDQC) site was officially added to Boeing’s Qualified Producers List (QPL) on May 1 and initiated qualified production on May 15 by manufacturing its first part under the Boeing contract. This milestone is a culmination of recent company successes including certification under AS9100D and the October 2017 dedication of PDQC by New York Governor Andrew Cuomo. “We could not be prouder of our Plattsburgh, New York production operations as they put another stake in the ground for the continued success of Norsk Titanium and the state of New York,” said NTi’s Chief Operating Officer Tamara Morytko. “Receiving this qualification from Boeing, now qualifying two NTi sites for production across the globe, is a true vote of confidence in o

Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus18.6.2018 15:00Tiedote

Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking procedure to treat patients with progressive keratoconus. Keratoconus is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens and is the leading cause of penetrating keratoplasty (corneal transplant) in the United States1. The Phase 3 clinical trial, ACP-KXL-308, is a multicenter, randomized, controlled study of a novel corneal cross-linking procedure of 275 patients with progressive keratoconus across approximately 20 sites in the United States. As is typical for U.S. Food and Drug Administration (FDA) drug trials, investigational treatments are provided at no cost to participating patients. “As a practitioner who has treated many p

LG Chem Hosts Global Innovation Contest 2018 (GIC 2018)"Finding Innovations to Change the World"18.6.2018 14:00Tiedote

LG Chem (KRX: 051910) is exploring innovative technologies that will change the world. LG Chem announced that it would hold a Global Innovation Contest (GIC) for leading universities and research institutions around the world. This is the first time that a Korean chemical company is conducting technology contests for the entire world. From June 18th to September 30th, 2018, LG Chem will accept innovative technology ideas in five promising business areas: Energy, Environment, Functional materials, Bio technology and Platform technology. Global scholars and researchers who are interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcomed to participate and submit the technical proposal through the official website (www.rnd.lgchem.com/global/gic). LG Chem will select internal experts and selection committees to evaluate the proposals considering technology innovation, marketability, and price competitiveness. Selected assign

Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)18.6.2018 14:00Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. Reimbursement is effective from July 1. The innovative, long-term access agreement also provides a framework for the assessment and access of our future CF medicines. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex. “We commend the Swedish authorities for partnering with us on an innovative, long-term access agreement. In countries where Vertex remains actively involved in reimbursement discussions, we encourage these health authorities and governments to match the commitment

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06Tiedote

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme